The DOI matches its Crossref record.
Aerosol Antibiotics in Cystic Fibrosis
Abstract
Chronic airways infection and inflammation is the greatest source of morbidity and mortality in cystic fibrosis (CF) patients. Many organisms can be found in the lower respiratory tract of CF patients, but infection with mucoid Pseudomonas aeruginosa is common, is associated with poorer outcomes, and is the main target for antimicrobial strategies in CF. Aerosol antibiotics achieve high local concentrations in the airways, reduce systemic toxicity, and have been used successfully for chronic suppressive treatment for established P. aeruginosa infections. Eradication of early P. aeruginosa airway infection has also been tried with aerosol antibiotics, though the ideal treatment strategy is still being investigated. There are several variables to consider when choosing an antibiotic formulation to develop for topical inhalation. Tobramycin solution for inhalation (TSI) is currently the only approved inhaled antibiotic in the United States. The time burden for patients to administer TSI by jet nebulizer is substantial, so efforts have focused on more efficient, faster delivery methods. Novel formulations of aerosol antibiotics are being studied for CF, including beta-lactams, fluoroquinolones and aminoglycosides. Phase-3 studies of aztreonam lysinate for inhalation delivered via a proprietary eFlow nebulizer showed improved outcomes and a short (< 3 min) delivery time. Liposome formulations are being studied as a way to penetrate mucoid biofilms and prolong the residence time of the antibiotic in the lungs. Light, porous, dry-powder formulations are also in clinical trials to reduce delivery time. These new formulations and delivery systems promise to expand our armamentarium against microbes while reducing the time burden for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology
Geller, D. E., Weers, J., & Heuerding, S. (2011) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2010.0855 · Cited by 308
Self-citationUngaro, F., d'Angelo, I., Coletta, C., d'Emmanuele di Villa Bianca, R., Sorrentino, R., Perfetto, B., Tufano, M. A., Miro, A., La Rotonda, M. I., & Quaglia, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.010 · Cited by 297
Le Noci, V., Guglielmetti, S., Arioli, S., Camisaschi, C., Bianchi, F., Sommariva, M., Storti, C., Triulzi, T., Castelli, C., Balsari, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.090 · Cited by 270
Metadata
- Authors
- Geller, D. E.
- Venue
- Respiratory Care
- Publisher
- SAGE Publications
- Published
- 2009
- Volume
- 54
- Issue
- 5
- Pages
- 658-670
- ISSN
- 0020-1324 (ISSN-L)
- OpenAlex
- W2146799440
- Cited by
- 160
- References
- 0
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aerosol Antibiotics in Cystic Fibrosis. https://app.cochat.ai/papers/10.4187/aarc0537
- The paper
- Geller, D. E. (2009). Aerosol Antibiotics in Cystic Fibrosis. Respiratory Care. https://doi.org/10.4187/aarc0537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.